Hospital of Saint Raphael, New Haven, CT, USA.
J Clin Lipidol. 2008 Oct;2(5):328-34. doi: 10.1016/j.jacl.2008.08.430. Epub 2008 Aug 15.
Ezetimibe is a synthetic 2-azetidinone that inhibits the absorption of sterols, including cholesterol, in the intestine. It is used as monotherapy or in combination with statins to reduce low-density lipoprotein cholesterol (LDL-C). Although extremely well-tolerated, there are reports of myopathy associated with ezetimibe. We performed a PubMed search through April 2008 to identify English language articles examining ezetimibe safety as monotherapy or in combination with other lipid-lowering agents. The incidence of musculoskeletal disorders in clinical trials using ezetimibe alone or in combination with statins is identical to placebo or the statin alone, respectively. We identified only six case reports of possible ezetimibe-associated myopathy. We concluded that ezetimibe neither produces nor exacerbates statin myopathy except, possibly, in rare cases.
依折麦布是一种合成的 2-氮杂环丁酮，可抑制肠道内固醇类物质（包括胆固醇）的吸收。该药可单药使用或与他汀类药物联合使用，降低低密度脂蛋白胆固醇（LDL-C）。尽管该药具有极好的耐受性，但有报告称其可引起肌病。我们通过 PubMed 检索，对 2008 年 4 月前发表的评估依折麦布单药或与其他降脂药物联合应用安全性的英文文献进行了分析。依折麦布单药或与他汀类药物联合应用临床试验中肌肉骨骼疾病的发生率与安慰剂或他汀类药物单药治疗组相同。我们仅发现 6 例可能与依折麦布相关的肌病的病例报告。我们的结论是，依折麦布既不会引起也不会加重他汀类药物引起的肌病，可能仅在极少数情况下除外。
